

Single-strand conformation polymorphism (SSCP) at the D8S86 locus

M.Iizuka, K.Hayashi and T.Sekiya

Oncogene Division, National Cancer Center Research Institute, 1-1, Tsukiji 5-Chome, Chuo-ku, Tokyo 104, Japan

Source/Description: pNCO907 contains a 500-bp *Pst*I fragment of pNCO901 inserted into pUC19 as described previously (1). The sequences for PCR primers were determined. A fragment of about 500-bp is amplified.

PCR Primers:

8.86-1 = TATCAGATAGAATGTGTGGG
8.86-2 = CTCTGAGGCCATGGAACAGA

Polymorphism: Two types of alleles (D1 and D2) were found by SSCP analysis.

Frequencies:

D1 = 0.64,
D2 = 0.36

Determined in 14 unrelated individuals. The observed heterozygosity is 0.50.

Chromosomal Localization: Chromosome 8, assigned with a panel of human-mouse somatic cell hybrids (1).

Mendelian Inheritance: Codominant segregation, observed in one informative family (Figure).

PCR and SSCP Conditions: 5'-end-labelled primers (0.5 pmol each) were added to a 5 μ l mixture of 50 ng genomic DNA, 1 \times PCR buffer specified by Cetus Corporation, 125 μ M concentrations of deoxynucleotide triphosphates (dATP, dCTP, dTTP and dGTP), and 0.125U *Taq* DNA polymerase. Thermal conditions were 32 cycles at 94°C for 20 sec and at 65°C for 2 min (2). Denatured PCR products were separated at 30 W at room temperature in 5% polyacrylamide gel containing 5% glycerol with vigorous cooling.

Other Comments: The probe pNCO907 also detects three RFLPs (*Eco*RI, *Sph*I and *Taq*I) (3).

Acknowledgements: This work was supported in part by a Grant-in-Aid from the Ministry of Health and Welfare for a Comprehensive 10-Year Strategy for Cancer Control, Japan, a Grant-in-Aid for Cancer Research from the Ministry of Education, Science and Culture, and a grant from the Special Condition Fund of the Science and Technology Agency of Japan.

References: 1) Iizuka, M. *et al.* (1990) *Cancer Res.* **50**, 3345-3350. 2) Mashiyama, S. *et al.* (1990) *Technique* **2**, 304-306. 3) Iizuka, M. *et al.* (1991) *Nucl. Acids Res.* **19**, 680.

HindIII-polymorphism in the LPL-gene detected by PCR

T.Bruin, P.W.A.Reymer, B.E.Groenemeyer, P.J.Talmud¹ and J.J.P.Kastelein

Division of Hemostasis, Thrombosis and Atherosclerosis, Academic Medical Center, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands and ¹Charing Cross Sunley Research Centre, 1 Lurgan Avenue, Hammersmith, London, W6 8LW, UK

Source/Description: We designed two oligonucleotides derived from the sequences in exon 8 and 9 in the LPL-gene (1) to amplify the sequence around a polymorphic HindIII-site. This polymorphism is located in intron 8 (2), in contrast to the HindIII-polymorphism in the 3' untranslated region as described by Oka *et al.* (3). The amplified fragment has a size of 1200 bp. The polymorphism in intron 8 was detected upon digestion of the PCR-product with HindIII.

Primer Sequences:

Hind5: 5'-AGTGATTCATACTTTAGCTG-3'
Hind3: 5'-TGAGACACTTTCTCCCTAGA-3'

Frequency:

	Heinzmann <i>et al.</i> (5) (n = 131)	Funke <i>et al.</i> (4) (n = 50)	PCR-method (n = 20)
Allele H1 (1200 bp)	0.33	0.26	0.25
Allele H2 (600 bp)	0.67	0.74	0.75

Chromosomal Location: The LPL-gene is located on chromosome 8p22 (6).

Reaction Conditions and Analysis: We used genomic DNA in the PCR-reaction. The primer-concentration is 160 ng/ml, the Mg⁺⁺-concentration is 2 mM and the dNTP-concentration is 200 μ M. The temperature profile is a) denaturation for 1 min at 95°C, b) annealing for 1 min at 50°C and c) extension for 1 min at 72°C. We used 30 cycles. The reaction products were analysed on 2% agarose in TBE after HindIII-digestion.

References: 1) Wion, K.L. *et al.* (1987) *Science* **235**, 1638-1641. 2) Kirchgessner, T.G. *et al.* (1989) *Proc. Natl. Acad. Sci. USA* **86**, 9647-9651. 3) Oka, K. *et al.* (1990) *Biochem. Biophys. Acta* **1049**, 21-26. 4) Funke, H. *et al.* (1987) *Nucl. Acids Res.* **15**, 9102. 5) Heinzmann, C. *et al.* (1987) *Nucl. Acids Res.* **15**, 6763. 6) Sparkes, R.S. *et al.* (1987) *Genomics* **1**, 138-144.




Figure 1. Individuals who are homozygous for presence (lane 2) or absence (lane 4), or who are heterozygous for the HindIII- restriction site (lane 3). The DNA-molecular weight marker (lane 1 + 5) is a combination of λ -DNA cut with HindIII and ϕ X-174-RF DNA cut with HaeIII.